Table 3. Proportional Hazards Models for Postacute Sequelae of SARS-CoV-2 Infection Unrelated to Multisystem Inflammatory Syndrome in Children Defined by Syndromic Features, Systemic Conditions, Medications Features, or All 3a.
| Predictor | Adjusted hazard ratios (95% CI) | |||
|---|---|---|---|---|
| Syndromic | Systemic | Medication | Any syndromic, systemic, or medication | |
| Viral test result and ICU level care | ||||
| Viral test–negative and no ICU care | 1 [Reference] | 1 [Reference] | 1 [Reference] | 1 [Reference] |
| Viral test–positive and no ICU care | 1.10 (1.07-1.12) | 1.54 (1.50-1.58) | 1.25 (1.22-1.28) | 1.22 (1.20-1.24) |
| Viral test–negative with ICU care | 1.22 (1.19-1.26) | 1.49 (1.43-1.55) | 2.00 (1.94-2.07) | 1.35 (1.32-1.39) |
| Viral test–positive with ICU care | 1.99 (1.78-2.23) | 3.40 (2.99-3.86) | 2.76 (2.39-3.18) | 2.11 (1.91-2.34) |
| Age, y | ||||
| <1 | 2.35 (2.31-2.39) | 2.08 (2.03-2.14) | 2.15 (2.10-2.20) | 1.86 (1.83-1.89) |
| 1-4 | 1.48 (1.46-1.50) | 1.57 (1.54-1.61) | 1.55 (1.52-1.58) | 1.49 (1.47-1.50) |
| 5-11 | 1 [Reference] | 1 [Reference] | 1 [Reference] | 1 [Reference] |
| 12-15 | 1.06 (1.04-1.08) | 1.54 (1.50-1.58) | 1.19 (1.16-1.21) | 1.24 (1.22-1.26) |
| 16-20 | 0.99 (0.97-1.01) | 1.42 (1.38-1.46) | 1.21 (1.18-1.24) | 1.16 (1.14-1.18) |
| Sex | ||||
| Female | 1 [Reference] | 1 [Reference] | 1 [Reference] | 1 [Reference] |
| Male | 0.93 (0.92-0.94) | 1.05 (1.03-1.07) | 0.98 (0.97-0.99) | 0.97 (0.96-0.98) |
| Race and ethnicityb | ||||
| Asian/Pacific Islander | 1 [Reference] | 1 [Reference] | 1 [Reference] | 1 [Reference] |
| Non-Hispanic Black | 1.04 (1.01-1.08) | 1.15 (1.10-1.20) | 1.42 (1.36-1.47) | 1.20 (1.17-1.23) |
| Hispanic | 1.00 (0.97-1.03) | 1.15 (1.10-1.20) | 1.25 (1.20-1.29) | 1.11 (1.08-1.13) |
| Multiple races | 0.96 (0.92-1.00) | 1.03 (0.97-1.09) | 1.03 (0.98-1.08) | 0.98 (0.95-1.02) |
| White | 0.85 (0.83-0.88) | 0.83 (0.80-0.87) | 0.87 (0.84-0.90) | 0.84 (0.83-0.86) |
| Other or unknown | 0.82 (0.79-0.84) | 0.80 (0.76-0.84) | 0.73 (0.70-0.77) | 0.78 (0.76-0.80) |
| Viral testing date | ||||
| March-June 2020 | 1.38 (1.35-1.41) | 1.31 (1.27-1.35) | 1.59 (1.55-1.64) | 1.42 (1.40-1.45) |
| July-October 2020 | 1.13 (1.11-1.15) | 1.06 (1.04-1.09) | 1.12 (1.09-1.14) | 1.12 (1.10-1.13) |
| November 2020-February 2021 | 1.17 (1.15-1.19) | 1.13 (1.10-1.16) | 1.13 (1.10-1.15) | 1.10 (1.09-1.12) |
| March-June 2021 | 1.28 (1.26-1.30) | 1.28 (1.25-1.31) | 1.33 (1.31-1.36) | 1.20 (1.19-1.22) |
| July-November 2021 | 1 [Reference] | 1 [Reference] | 1 [Reference] | 1 [Reference] |
| Chronic conditions | ||||
| None | 1 [Reference] | 1 [Reference] | 1 [Reference] | 1 [Reference] |
| Noncomplex | 1.58 (1.56-1.61) | 1.62 (1.58-1.65) | 1.84 (1.80-1.87) | 1.92 (1.89-1.94) |
| Complex | 3.33 (3.29-3.38) | 3.30 (3.23-3.36) | 3.64 (3.57-3.70) | 3.68 (3.64-3.72) |
Abbreviation: ICU, intensive care unit.
a
Regression models are adjusted for institution.
b
Race and ethnicity data were collected by self-report. The other race category includes patients whose race was categorized as American Indian or Alaska Native or as other.